Q3-osavuosiraportti
UUTTA
1 päivä sitten‧1 t
Tarjoustasot
Oslo Børs
Määrä
Osto
213
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 185 | - | - | ||
| 111 | - | - | ||
| 309 | - | - | ||
| 216 | - | - | ||
| 300 | - | - |
Ylin
26,3VWAP
Alin
24,2VaihtoMäärä
1,6 63 922
VWAP
Ylin
26,3Alin
24,2VaihtoMäärä
1,6 63 922
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 27.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11 t sittenHere's what ChatGPT says: Reason for the fall • The company reported third quarter 2025 with revenue of approx. NOK 29.8 mill, up ~24 % from the same quarter last year.  • EBITDA turned positive at approx. NOK 3.5 mill in Q3, compared to a loss of NOK 2.3 mill in Q3 2024.  • Nevertheless, the market reacted negatively because revenue “disappointed” a little – it was reported that the company had an estimate around NOK 31.45 mill that the market expected, while they delivered ~NOK 29.8 mill.  • In addition, it is mentioned that even though Q3 was good, for the 9-month period (first nine months), revenue has only increased by approx. 2 % or even been slightly down compared to the same period last year.  • Furthermore, there is sector and market risk: the company is in the biotech/enzyme segment, which often has high expectations of strong growth – even if the figures are good in absolute terms, they can be considered “moderate” in relation to expectations. Conclusion: Yes — the fall is partly rational and explainable. Even though the company delivered growth and positive operations, the delivery was not fully in line with the higher expectations, and growth for the year so far is relatively moderate. The market punished – or reallocated – expectations. ⸻ Historical and expectation vs. delivery • Historically, ArcticZymes has had varying growth: For example, in Q2/9-mnd 2025, they reported only ~5 % growth in Q2, and a decline for the first 6-9 months.  • So Q3 with +24 % is a clear improvement – but the market looks at the full year and underlying trend, not just Q3. • Expectations: Analyses show that the market expected more than what was delivered in Q3 (as mentioned above). So “better” figures were expected. • The company itself says that they have “continued growth momentum” and emphasizes signing partnerships (e.g., with Brenntag Specialists Pharma in Europe) as an important strategic element.  ⸻ What the company says and what the analysts say The company says: • “Q3 reflects continued execution of our customer-centric strategy …” stated CEO Michael Akoh.  • They highlight growth in both the “Biomanufacturing” and “Molecular Tools” segments, especially increased sales of GMP-grade products, and the European distribution agreement with Brenntag as a milestone.  • They also warn that a couple of large customers are significant for the underlying business, and that currency and timing effects can influence.  Analysts say / the rating: • According to MarketScreener: Analysts are generally positive – the average recommendation is “Overweight” or “Buy”.  • On the other hand, the analysis from SimplyWallSt pointed out that the company's price-to-sales multiples are relatively high compared to the industry, and that to justify this, the company must deliver growth well above average.  • Future estimates show that EPS and revenues are expected to grow significantly: for example, EPS is expected to grow ~80 % per year and revenues ~19–20 % per year in the coming three years.  ⸻ Is it likely that the fall continues today? There are several factors that can influence whether the fall continues or not: • If the market still interprets that the company does not deliver sufficiently in relation to high expectations, the decline may continue or the stock may be held low until new data/indicators. • If the company or the market provides new positive signals (for example, larger orders, contracts, or strong future forecasts), the price may stabilize or turn around. • Given that the report is already public and there was some disappointment in relation to expectations, much of the fall may already be priced in – so the risk of further fall is perhaps somewhat reduced, but still present (especially if something negative becomes clear). • For you as an investor: be aware of news about contracts, customer losses, currency effects, and how the segments deliver going forward – this will be key to whether the stock turns around or falls further. ⸻ Summary • ArcticZymes delivered a solid Q3 with 24 % growth and positive EBITDA, but the market wanted higher revenue and stronger growth / a clearer “turnaround”. • The fall is therefore understandable – not because the company delivered poorly, but because the delivery was not strong enough in relation to the market's high expectations. • Analysts are generally positive, but pricing and expectations are high – the risk that the company must deliver a lot to meet them. • Whether the price continues to fall today depends on whether new negative signals emerge. Without new negative news, the price may stabilize, but uncertainty is high.
·1 päivä sittenThat was quite a reaction!?
·1 päivä sittenOthers also think it was a strong reaction - but in the end, we ended up roughly where we started (we started the day at approx. 26.30) - from Pareto: "Solid report with sales in line and EBITDA slightly above expectations. Shares closed down 6% and the negative market reaction was likely driven by overextrapolation from Q2 Biomanufacturing. We make only minor sales revisions but lower opex, lifting EBITDA. With no fundamental change to the story, we raise our TP to NOK 31 (29) and see ~20% upside at current levels. Accordingly, we upgrade to Buy (Hold)."
·26.8.Has stabilized around 29,- it seems, there must be some price-driving information for this to climb further. In any case, the increase we have had in recent months has brought back some optimism among us small shareholders again. What do you think will be needed to drive the price further now?·27.8.The company needs to show that they are on the right track, that sales are increasing quarter by quarter, that growth is simply back. Between the quarterly presentations, I would think that announcements of major agreements/collaborations, etc. will help lift the stock. New products with obvious potential will probably be positive.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
UUTTA
1 päivä sitten‧1 t
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenHere's what ChatGPT says: Reason for the fall • The company reported third quarter 2025 with revenue of approx. NOK 29.8 mill, up ~24 % from the same quarter last year.  • EBITDA turned positive at approx. NOK 3.5 mill in Q3, compared to a loss of NOK 2.3 mill in Q3 2024.  • Nevertheless, the market reacted negatively because revenue “disappointed” a little – it was reported that the company had an estimate around NOK 31.45 mill that the market expected, while they delivered ~NOK 29.8 mill.  • In addition, it is mentioned that even though Q3 was good, for the 9-month period (first nine months), revenue has only increased by approx. 2 % or even been slightly down compared to the same period last year.  • Furthermore, there is sector and market risk: the company is in the biotech/enzyme segment, which often has high expectations of strong growth – even if the figures are good in absolute terms, they can be considered “moderate” in relation to expectations. Conclusion: Yes — the fall is partly rational and explainable. Even though the company delivered growth and positive operations, the delivery was not fully in line with the higher expectations, and growth for the year so far is relatively moderate. The market punished – or reallocated – expectations. ⸻ Historical and expectation vs. delivery • Historically, ArcticZymes has had varying growth: For example, in Q2/9-mnd 2025, they reported only ~5 % growth in Q2, and a decline for the first 6-9 months.  • So Q3 with +24 % is a clear improvement – but the market looks at the full year and underlying trend, not just Q3. • Expectations: Analyses show that the market expected more than what was delivered in Q3 (as mentioned above). So “better” figures were expected. • The company itself says that they have “continued growth momentum” and emphasizes signing partnerships (e.g., with Brenntag Specialists Pharma in Europe) as an important strategic element.  ⸻ What the company says and what the analysts say The company says: • “Q3 reflects continued execution of our customer-centric strategy …” stated CEO Michael Akoh.  • They highlight growth in both the “Biomanufacturing” and “Molecular Tools” segments, especially increased sales of GMP-grade products, and the European distribution agreement with Brenntag as a milestone.  • They also warn that a couple of large customers are significant for the underlying business, and that currency and timing effects can influence.  Analysts say / the rating: • According to MarketScreener: Analysts are generally positive – the average recommendation is “Overweight” or “Buy”.  • On the other hand, the analysis from SimplyWallSt pointed out that the company's price-to-sales multiples are relatively high compared to the industry, and that to justify this, the company must deliver growth well above average.  • Future estimates show that EPS and revenues are expected to grow significantly: for example, EPS is expected to grow ~80 % per year and revenues ~19–20 % per year in the coming three years.  ⸻ Is it likely that the fall continues today? There are several factors that can influence whether the fall continues or not: • If the market still interprets that the company does not deliver sufficiently in relation to high expectations, the decline may continue or the stock may be held low until new data/indicators. • If the company or the market provides new positive signals (for example, larger orders, contracts, or strong future forecasts), the price may stabilize or turn around. • Given that the report is already public and there was some disappointment in relation to expectations, much of the fall may already be priced in – so the risk of further fall is perhaps somewhat reduced, but still present (especially if something negative becomes clear). • For you as an investor: be aware of news about contracts, customer losses, currency effects, and how the segments deliver going forward – this will be key to whether the stock turns around or falls further. ⸻ Summary • ArcticZymes delivered a solid Q3 with 24 % growth and positive EBITDA, but the market wanted higher revenue and stronger growth / a clearer “turnaround”. • The fall is therefore understandable – not because the company delivered poorly, but because the delivery was not strong enough in relation to the market's high expectations. • Analysts are generally positive, but pricing and expectations are high – the risk that the company must deliver a lot to meet them. • Whether the price continues to fall today depends on whether new negative signals emerge. Without new negative news, the price may stabilize, but uncertainty is high.
- ·1 päivä sittenThat was quite a reaction!?·1 päivä sittenOthers also think it was a strong reaction - but in the end, we ended up roughly where we started (we started the day at approx. 26.30) - from Pareto: "Solid report with sales in line and EBITDA slightly above expectations. Shares closed down 6% and the negative market reaction was likely driven by overextrapolation from Q2 Biomanufacturing. We make only minor sales revisions but lower opex, lifting EBITDA. With no fundamental change to the story, we raise our TP to NOK 31 (29) and see ~20% upside at current levels. Accordingly, we upgrade to Buy (Hold)."
- ·26.8.Has stabilized around 29,- it seems, there must be some price-driving information for this to climb further. In any case, the increase we have had in recent months has brought back some optimism among us small shareholders again. What do you think will be needed to drive the price further now?·27.8.The company needs to show that they are on the right track, that sales are increasing quarter by quarter, that growth is simply back. Between the quarterly presentations, I would think that announcements of major agreements/collaborations, etc. will help lift the stock. New products with obvious potential will probably be positive.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
213
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 185 | - | - | ||
| 111 | - | - | ||
| 309 | - | - | ||
| 216 | - | - | ||
| 300 | - | - |
Ylin
26,3VWAP
Alin
24,2VaihtoMäärä
1,6 63 922
VWAP
Ylin
26,3Alin
24,2VaihtoMäärä
1,6 63 922
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 27.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
UUTTA
1 päivä sitten‧1 t
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 27.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenHere's what ChatGPT says: Reason for the fall • The company reported third quarter 2025 with revenue of approx. NOK 29.8 mill, up ~24 % from the same quarter last year.  • EBITDA turned positive at approx. NOK 3.5 mill in Q3, compared to a loss of NOK 2.3 mill in Q3 2024.  • Nevertheless, the market reacted negatively because revenue “disappointed” a little – it was reported that the company had an estimate around NOK 31.45 mill that the market expected, while they delivered ~NOK 29.8 mill.  • In addition, it is mentioned that even though Q3 was good, for the 9-month period (first nine months), revenue has only increased by approx. 2 % or even been slightly down compared to the same period last year.  • Furthermore, there is sector and market risk: the company is in the biotech/enzyme segment, which often has high expectations of strong growth – even if the figures are good in absolute terms, they can be considered “moderate” in relation to expectations. Conclusion: Yes — the fall is partly rational and explainable. Even though the company delivered growth and positive operations, the delivery was not fully in line with the higher expectations, and growth for the year so far is relatively moderate. The market punished – or reallocated – expectations. ⸻ Historical and expectation vs. delivery • Historically, ArcticZymes has had varying growth: For example, in Q2/9-mnd 2025, they reported only ~5 % growth in Q2, and a decline for the first 6-9 months.  • So Q3 with +24 % is a clear improvement – but the market looks at the full year and underlying trend, not just Q3. • Expectations: Analyses show that the market expected more than what was delivered in Q3 (as mentioned above). So “better” figures were expected. • The company itself says that they have “continued growth momentum” and emphasizes signing partnerships (e.g., with Brenntag Specialists Pharma in Europe) as an important strategic element.  ⸻ What the company says and what the analysts say The company says: • “Q3 reflects continued execution of our customer-centric strategy …” stated CEO Michael Akoh.  • They highlight growth in both the “Biomanufacturing” and “Molecular Tools” segments, especially increased sales of GMP-grade products, and the European distribution agreement with Brenntag as a milestone.  • They also warn that a couple of large customers are significant for the underlying business, and that currency and timing effects can influence.  Analysts say / the rating: • According to MarketScreener: Analysts are generally positive – the average recommendation is “Overweight” or “Buy”.  • On the other hand, the analysis from SimplyWallSt pointed out that the company's price-to-sales multiples are relatively high compared to the industry, and that to justify this, the company must deliver growth well above average.  • Future estimates show that EPS and revenues are expected to grow significantly: for example, EPS is expected to grow ~80 % per year and revenues ~19–20 % per year in the coming three years.  ⸻ Is it likely that the fall continues today? There are several factors that can influence whether the fall continues or not: • If the market still interprets that the company does not deliver sufficiently in relation to high expectations, the decline may continue or the stock may be held low until new data/indicators. • If the company or the market provides new positive signals (for example, larger orders, contracts, or strong future forecasts), the price may stabilize or turn around. • Given that the report is already public and there was some disappointment in relation to expectations, much of the fall may already be priced in – so the risk of further fall is perhaps somewhat reduced, but still present (especially if something negative becomes clear). • For you as an investor: be aware of news about contracts, customer losses, currency effects, and how the segments deliver going forward – this will be key to whether the stock turns around or falls further. ⸻ Summary • ArcticZymes delivered a solid Q3 with 24 % growth and positive EBITDA, but the market wanted higher revenue and stronger growth / a clearer “turnaround”. • The fall is therefore understandable – not because the company delivered poorly, but because the delivery was not strong enough in relation to the market's high expectations. • Analysts are generally positive, but pricing and expectations are high – the risk that the company must deliver a lot to meet them. • Whether the price continues to fall today depends on whether new negative signals emerge. Without new negative news, the price may stabilize, but uncertainty is high.
- ·1 päivä sittenThat was quite a reaction!?·1 päivä sittenOthers also think it was a strong reaction - but in the end, we ended up roughly where we started (we started the day at approx. 26.30) - from Pareto: "Solid report with sales in line and EBITDA slightly above expectations. Shares closed down 6% and the negative market reaction was likely driven by overextrapolation from Q2 Biomanufacturing. We make only minor sales revisions but lower opex, lifting EBITDA. With no fundamental change to the story, we raise our TP to NOK 31 (29) and see ~20% upside at current levels. Accordingly, we upgrade to Buy (Hold)."
- ·26.8.Has stabilized around 29,- it seems, there must be some price-driving information for this to climb further. In any case, the increase we have had in recent months has brought back some optimism among us small shareholders again. What do you think will be needed to drive the price further now?·27.8.The company needs to show that they are on the right track, that sales are increasing quarter by quarter, that growth is simply back. Between the quarterly presentations, I would think that announcements of major agreements/collaborations, etc. will help lift the stock. New products with obvious potential will probably be positive.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
213
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 185 | - | - | ||
| 111 | - | - | ||
| 309 | - | - | ||
| 216 | - | - | ||
| 300 | - | - |
Ylin
26,3VWAP
Alin
24,2VaihtoMäärä
1,6 63 922
VWAP
Ylin
26,3Alin
24,2VaihtoMäärä
1,6 63 922
Välittäjätilasto
Dataa ei löytynyt